WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Adfinitas Health
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Research, Industry Outlook
PRnewswire | July 06, 2023
LuminUltra today announced the launch of BugCount® Fuel, an innovative, user-friendly test kit to quickly and accurately evaluate fuels for microbial contamination which can cause significant challenges for a range of industries including aviation, marine, and fuel handling. Microbiological testing of fuel is critical for identifying and getting ahead of issues that lead to compromised performance, including clogged filters, worn injectors, fuel tank lining (pitting) corrosi...
Medical
Hillstream | June 30, 2022
Hillstream BioPharma, Inc., a U.S.-based biotechnology company developing novel therapeutic candidates targeting ferroptosis for cancer treatment, announced a collaboration with an Indian pioneer biobank and peonalized medicine company that leverages Saarum Innovation's global life sciences research expertise, Sapien Biosciences. The collaboration is aimed at assessing the compatibility of HSB-1216 with immune checkpoint inhibitors. HSB-1216, Hillstream’s most advanced c...
MedTech
SpectrumX | November 25, 2022
SpectrumX, a UK-based healthcare and pharmaceutical company announces that following a constructive scientific advice meeting with the Medicines and Healthcare products Regulatory Agency on Monday, 14th November, the Company is prepared to move forward with the next stage in clinical development of its respiratory drug candidate SPX-001. Per regulatory guidelines, SpectrumX will submit a combined Clinical Trial and Ethics Committee application for a placebo-controlled phase Ib inf...
Cell and Gene Therapy
Bio-Techne | February 25, 2021
Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...
Video
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE